Abstract library

750 results for "long-term survival".
#36 A monocentric analysis of patients with pulmonary neuroendocrine tumors over 15 years: long term survival and life quality dependent from histological subtypes and surgical management
Introduction: Pulmonary neuroendocrine tumors substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized interdisciplinary centers, a broad therapeutical armentarium can be used to achieve optimal treatment.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Johannes N Hoffmann
Authors: Zahn S, Hornung H, Schick K S, Winter H, ...
#326 Long-term Survival and Quality of Life in Patients with Ileum NET: A Single Center Experience
Introduction: Neuroendocrine tumors of the small bowel can be differentiated in terms of progression, survival time and health-related quality of life from endothelial tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Anne Reincke
Authors: Reincke A, Zahn S, Hornung H, Jauch K W, ...
#662 Sequlae and Survivorship in Neuroendocrine Patients Treated with 131I-MIBG
Introduction: Radionuclide therapy in the form of 131I-MIBG has been in therapeutic use since the 1980s. Newer modalities are emerging for the treatment of neuroendocrine and chromaffin cell tumors, but many of these do not yet have adequate long-term follow-up to determine longer term efficacy and sequelae.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Wing-Chiu C Sze
Authors: Sze C, Grossman A, Amendra D, Shieh S, ...
#599 Rectal Neuroendocrine Tumors: Long-Term Survival After Resection and Prognostic Factors
Introduction: The rectum is the third most common location for gastrointestinal carcinoids after small bowel and colon. Due to their rarity, the characteristics and behavior of this unusual malignancy remain unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Cai Jianqiang
Authors: Du F, Chi Y H B L, Zhao H, Wang J W, ...
#664 Natural Course and Survival of Thymic and Bronchopulmonary Neuroendocrine Tumors are Different for Male and Female MEN-1 Patients
Introduction: The course of thymic- and bronchopulmonary neuroendocrine tumors (Th- and Bp-NET) in MEN-1 patients is still unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Joanne De Laat
#1348 Resectable Primary Tumor in Patients with Pancreatic Neuroendocrine Tumors Located to the Body or Tail and Unresectable Liver Metastases: Does Distal Pancreatectomy Improve Survival?
Introduction: The role of primary tumor surgery in pancreatic neuroendocrine tumor (PNET) with unresectable liver metastases is controversial and international guidelines do not recommend surgery in that setting of patients
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Dr Emilio Bertani
Authors: Bertani E, Fazio N, Grana C, Chiappa A, ...
#1473 Long-term Outcomes of Colorectal Neuroendocrine Tumors: A Sub Group Analysis of 29 G3 Cases According to the 2010 WHO Classification
Introduction: Colorectal neuroendocrine tumors (NETs) are a group of heterogenous neoplasm.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Jiahua Leng
Authors: Leng J, Li Z W, Li Y, Chen Z S, ...
#158 Progression-free survival (PFS) as a primary endpoint for clinical studies in advanced neuroendocrine tumors (NETs)
Introduction: Successfully testing new antitumor agents requires primary study endpoints that are clinically important, and also provide sufficient statistical power within a timeframe and population size that is feasible for the tumor type. Using overall survival (OS) as the primary endpoint in NET studies is challenging because of the low incidence (5.25/100,000 annually), disease heterogeneity, extended survival time (Yao 2008), and confounding effects of multiple therapies. These inherent aspects of NETs make OS an extremely difficult and challenging endpoint to evaluate clinical efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors: Singh S, Law C, ...
#745 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) for Patients with Neuroendocrine Tumors (NETs) with Metastatic Abdominal Localizations.
Introduction: There are only few case reports about surgery in patients affected by gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients previously underwent peptide receptor radionuclide therapy (PRRT).
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: MD Emilio Bertani
#134 Gastrointestinal neuroendocrine tumors: tumor characteristics and long-term clinical outcome in the German NET registry
Introduction: Prognosis of neuroendocrine tumors (NETs) has been difficult to predict due to heterogenous tumor biology, various classification systems, and lack of reliable and recent data due to the rarity of these tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Ulrich-Frank Pape
Authors: Maasberg S, König A, Rinke A, Anlauf M, ...